Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Other Accumulated Expenses (2016 - 2025)

Dexcom (DXCM) has disclosed Other Accumulated Expenses for 15 consecutive years, with $7.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 83.58% to $7.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.7 million, a 83.58% decrease, with the full-year FY2025 number at $7.7 million, down 83.58% from a year prior.
  • Other Accumulated Expenses was $7.7 million for Q4 2025 at Dexcom, down from $42.0 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $62.9 million in Q1 2022 to a low of $7.7 million in Q4 2025.
  • A 5-year average of $44.1 million and a median of $47.2 million in 2023 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: rose 24.66% in 2021, then plummeted 83.58% in 2025.
  • Dexcom's Other Accumulated Expenses stood at $54.6 million in 2021, then decreased by 27.29% to $39.7 million in 2022, then increased by 2.02% to $40.5 million in 2023, then rose by 15.8% to $46.9 million in 2024, then tumbled by 83.58% to $7.7 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Other Accumulated Expenses are $7.7 million (Q4 2025), $42.0 million (Q3 2025), and $50.3 million (Q1 2025).